In conclusion, results of this network meta‐analysis highlight that efficacy of JAK1 inhibitors including abrocitinib, baricitinib, and upadacitinib is consistently higher than those of placebo in moderate‐to‐severe AD. Here, JAK1 is linked to Alzheimer disease.